Research Focus
Does bone resorption inhibition affect the anabolic response to parathyroid hormone?

https://doi.org/10.1016/j.tem.2004.01.002Get rights and content

Abstract

One of the questions arising from the use of parathyroid hormone (PTH) as an anabolic agent is whether preventing bone loss with inhibitors of bone resorption might result in a greater amount of bone in response to PTH. Two recent independent reports indicate that the anabolic effect of PTH in osteoporotic women appears to be significantly reduced when alendronate is administered in combination with PTH in studies using biochemical markers, quantitative computed tomography and bone mineral density (BMD) measurements. The very different mechanisms of the two treatments reduces the impact of the BMD data, but if the overall conclusion is correct, an effect of PTH on resorption might be necessary for the anabolic effect to follow.

References (10)

  • S.R. Cummings

    Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

    Am. J. Med.

    (2002)
  • R.M. Neer

    Effect of parathyroid hormone(1-34) on fractures and bone mineral density in post-menopauasal women with osteoporosis

    N. Engl. J. Med.

    (2001)
  • D.M. Black

    The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

    N. Engl. J. Med.

    (2003)
  • J.S. Finkelstein

    The effects of parathyroid hormone, alendronate, or both in men with osteoporosis

    N. Engl. J. Med.

    (2003)
  • H. Dobnig et al.

    Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells

    Endocrinology

    (1995)
There are more references available in the full text version of this article.

Cited by (36)

  • Introducing a new method for evaluation of the interaction between an antigen and an antibody: Single frequency impedance analysis for biosensing systems

    2014, Talanta
    Citation Excerpt :

    Parathyroid hormone (PTH) is secreted from cells of parathyroid glands and has a vital role in the regulation of calcium and phosphorous concentration in extracellular fluid [1–3].

  • Bone remodelling: its local regulation and the emergence of bone fragility

    2008, Best Practice and Research: Clinical Endocrinology and Metabolism
    Citation Excerpt :

    The anabolic effect of PTH is lost in c-fos−/− mice that are osteopetrotic because of failure of osteoclast formation.57 Treatment of patients with osteoporosis with PTH and an anti-resorptive agent blunts the response to PTH58,59, implying that combining the anabolic PTH with anti-resorptive bisphosphonate would be associated with a less effective anabolic effect.60,61 Treatment of rats with a single subcutaneous injection of PTH results in a transient increase in mRNA for RANKL and a decrease in that for OPG, with maximum effect at 1 hour, and returning to control within 2 hours, consistent with a subtle or transient activation of the osteoclast that might be needed to prepare the bone surface for new matrix deposition.62

  • CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment

    2007, Bone
    Citation Excerpt :

    Our data indicate that CREM deficiency does not affect the increase in osteoblast surface and the bone formation rate seen in response to intermittent PTH, suggesting either that CREM is not involved in this response or that other ATF/CREB factors may have compensated for CREM. It has been suggested that the anabolic effect of PTH is mediated through effects on bone remodeling [29]. In WT mice, the effect on bone formation outweighed bone resorption, leading to an increase in bone mass.

  • Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis

    2006, Cell Metabolism
    Citation Excerpt :

    Mechanical forces and certain systemic factors, such as steroids or parathyroid hormone, affect bone remodeling. For the anabolic effect of parathyroid hormone to occur, bone resorption may be necessary, implying that osteoblast formation requires signals from osteoclasts (Martin, 2004). Local factors including TRAP secreted by osteoclasts (Sheu et al., 2003) and insulin-like growth factor and transforming growth factor-β, which are released from bone matrix during bone resorption (Hayden et al., 1995; Pfeilschifter and Mundy, 1987), can stimulate bone formation.

View all citing articles on Scopus
View full text